Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
DASA | RCV001824195 | SCV002073748 | likely pathogenic | Hereditary spastic paraplegia 49 | 2022-02-05 | criteria provided, single submitter | clinical testing | The c.1751del;p.(Gly584Glufs*62) is a null frameshift variant (NMD) in the TECPR2 gene and predicts alteration of the nonsense-mediate decay - NMD is present in a relevant exon to the transcript - PVS1. The variant is present at low allele frequencies population databases (rs1345546964– gnomAD 0.00006575%; ABraOM no frequency - http://abraom.ib.usp.br/) -PM2_supporting. In summary, the currently available evidence indicates that the variant is likely pathogenic. |
Labcorp Genetics |
RCV001824195 | SCV003007809 | pathogenic | Hereditary spastic paraplegia 49 | 2022-05-17 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with TECPR2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Gly584Glufs*62) in the TECPR2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TECPR2 are known to be pathogenic (PMID: 23176824, 25590979). |